Alector, Inc. (ALEC) stock
ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3069% below fair value
$2.54+0.09 (+3.67%)
Close on Nov 13, 2026Market cap $283.61MP/E 7.3Yield –
Alector EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Alector's EPS for the twelve months ending Sep 30, 2026 was $0.35. For fiscal 2025 it was -$1.39. The highest annual figure on record is -$0.45 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.39 | – |
| FY2024 | Dec 31, 2024 | -$1.23 | – |
| FY2023 | Dec 31, 2023 | -$1.56 | – |
| FY2022 | Dec 31, 2022 | -$1.62 | – |
| FY2021 | Dec 31, 2021 | -$0.45 | – |
| FY2020 | Dec 31, 2020 | -$2.45 | – |
| FY2019 | Dec 31, 2019 | -$1.71 | – |
| FY2018 | Dec 31, 2018 | -$4.62 | – |
| FY2017 | Dec 31, 2017 | -$3.55 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.11 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.21 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.21 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.34 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.34 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.30 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.41 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.02 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.43 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.40 | -2100.0% |
| Q1 FY2024 | Mar 31, 2024 | -$0.38 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.49 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.53 | – |
| Q2 FY2023 | Jun 30, 2023 | $0.02 | -83.3% |
| Q1 FY2023 | Mar 31, 2023 | -$0.55 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.63 | -142.3% |
| Q3 FY2022 | Sep 30, 2022 | -$0.56 | – |
| Q2 FY2022 | Jun 30, 2022 | $0.12 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.54 | – |
| Q3 FY2021 | Sep 30, 2021 | $1.49 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.69 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.66 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.66 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.67 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.58 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.53 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.45 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.47 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.36 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.42 | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.48 | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.34 | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.78 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?